Pulse Biosciences CS (PLSE) Stock Price, Quote & News

Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cyc...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 510 906 4600

Website: www.pulsebiosciences.com

Address:

601 Brickell Key Drive, Suite 1080, Miami, United States

ZTradeZone Nov. 28 at 8:03 PM

$PLSE niche medical tech mover with thin volume where real catalysts can completely reshape the chart

0 · Reply

TruthBroker2 Nov. 28 at 2:29 PM

$PLSE Good Friday Let Go

0 · Reply

Aurora_CrestCapital Nov. 28 at 1:58 PM

$PLSE At the end of the day my thesis on Mainz Biomed is simple - I’m buying a platform that targets CRC and pancreatic cancer, backed by real data and real partners, trading at about ~$6M with a published Wall Street price target of $14 (implying +1,328.57% upside), and for a small slice of my portfolio that’s exactly the kind of long-dated, high-conviction lottery ticket I’m willing to tuck away and let the combination of clinical readouts, geographic rollouts and sector M&A slowly do its work over the next few years 🚀

0 · Reply

Klinsmann Nov. 28 at 12:00 PM

$PLSE in

0 · Reply

TruthBroker2 Nov. 28 at 11:31 AM

$PLSE

0 · Reply

WallStreetBuyDip Nov. 28 at 1:06 AM

Comparing trending tickers $GWAV vs $PLSE: GWAV rose sharply, up 8.11% to $5.73, though on a notably low volume of just 16.4K shares compared to its average of 186.9K. Meanwhile, PLSE also gained, up 3.45% to $13.79 with a volume of 160.7K shares, closely aligning with its usual trading volume of 176.1K. GWAV exhibited a more significant price increase on much lighter trading, while PLSE's performance was more modest but on more consistent volume levels.

0 · Reply

WallStreetBuyDip Nov. 28 at 12:34 AM

Comparing trending tickers $GWAV vs $PLSE: $GWAV Massive volume spike with 16,400 shares traded compared to the average of 186,891. Price holding steady at $5.73 after recent fluctuations from $4.57 to $5.78. Waiting for a lower H% before considering an entry. Meanwhile, $PLSE Massive volume spikes recently with Nov 24 hitting 220,000 shares traded. Price range from $12.66 to $13.79. Average volume is 176,104. H% seems high, so smart move might be to wait for H% to cool down before entering.

0 · Reply

TruthBroker2 Nov. 28 at 12:03 AM

$PLSE

0 · Reply

WallStreetBuyDip Nov. 27 at 10:44 PM

Comparing trending tickers $PLSE vs $DUK: PLSE is up 3.45% to $13.79 with a trading volume of 160.7K shares, slightly below its average volume of 176.1K. In contrast, DUK has increased by 1.23% to $123.43, with its trading volume matching the average at 3.4M shares. While both stocks are seeing positive movements, PLSE shows a more significant percentage gain, though on slightly lower-than-average volume, whereas DUK's performance aligns closely with its typical trading activity.

0 · Reply

WallStreetBuyDip Nov. 27 at 10:19 PM

Comparing trending tickers $ETH.X vs $PLSE: ETH is up 3.33% to $28.55 with trading volume reaching 5.5 million shares, significantly above its average of 3.7 million. PLSE, meanwhile, has increased by 3.45% to $13.79, though its volume of 160.7K is slightly below the usual 176.1K. Both stocks are showing positive momentum, but ETH's volume surge suggests a stronger investor interest compared to PLSE's more modest trading activity.

0 · Reply

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 6, 2025, 4:05 PM EST - 23 days ago

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Nov 5, 2025, 11:01 PM EST - 24 days ago

Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 24 days ago

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

Oct 24, 2025, 7:00 AM EDT - 5 weeks ago

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

Oct 22, 2025, 4:05 PM EDT - 5 weeks ago

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Oct 10, 2025, 7:00 AM EDT - 7 weeks ago

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Oct 7, 2025, 7:00 AM EDT - 7 weeks ago

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Sep 10, 2025, 7:00 AM EDT - 2 months ago

Pulse Biosciences' nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

Sep 8, 2025, 7:00 AM EDT - 2 months ago

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Sep 2, 2025, 7:00 AM EDT - 3 months ago

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Aug 26, 2025, 7:00 AM EDT - 3 months ago

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Aug 12, 2025, 9:06 PM EDT - 3 months ago

Pulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 3 months ago

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

Aug 1, 2025, 7:00 AM EDT - 4 months ago

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

Jul 29, 2025, 4:05 PM EDT - 4 months ago

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

May 10, 2025, 11:02 PM EDT - 7 months ago

Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 7 months ago

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

May 6, 2025, 4:05 PM EDT - 7 months ago

Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

May 1, 2025, 7:00 AM EDT - 7 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting

Apr 24, 2025, 4:05 PM EDT - 7 months ago

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

Apr 23, 2025, 7:00 AM EDT - 7 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

Mar 27, 2025, 7:46 PM EDT - 8 months ago

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 8 months ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

Mar 26, 2025, 4:05 PM EDT - 8 months ago

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

Mar 7, 2025, 8:00 AM EST - 9 months ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

Feb 20, 2025, 4:05 PM EST - 10 months ago

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

Feb 4, 2025, 8:00 AM EST - 10 months ago

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Jan 30, 2025, 8:00 AM EST - 10 months ago

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

Jan 21, 2025, 7:00 AM EST - 11 months ago

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Jan 13, 2025, 7:00 AM EST - 11 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Jan 10, 2025, 8:00 AM EST - 11 months ago

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Jan 3, 2025, 9:00 AM EST - 11 months ago

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 4:30 PM EST - 1 year ago

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Dec 19, 2024, 8:00 AM EST - 1 year ago

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

Dec 17, 2024, 8:00 AM EST - 1 year ago

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Oct 31, 2024, 2:25 PM EDT - 1 year ago

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Oct 30, 2024, 9:42 PM EDT - 1 year ago

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Oct 30, 2024, 4:02 PM EDT - 1 year ago

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

Aug 12, 2024, 6:50 PM EDT - 1 year ago

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

Jul 8, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Jul 3, 2024, 2:44 PM EDT - 1 year ago

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

ZTradeZone Nov. 28 at 8:03 PM

$PLSE niche medical tech mover with thin volume where real catalysts can completely reshape the chart

0 · Reply

TruthBroker2 Nov. 28 at 2:29 PM

$PLSE Good Friday Let Go

0 · Reply

Aurora_CrestCapital Nov. 28 at 1:58 PM

0 · Reply

Klinsmann Nov. 28 at 12:00 PM

$PLSE in

0 · Reply

TruthBroker2 Nov. 28 at 11:31 AM

$PLSE

0 · Reply

WallStreetBuyDip Nov. 28 at 1:06 AM

0 · Reply

WallStreetBuyDip Nov. 28 at 12:34 AM

0 · Reply

TruthBroker2 Nov. 28 at 12:03 AM

$PLSE

0 · Reply

WallStreetBuyDip Nov. 27 at 10:44 PM

0 · Reply

WallStreetBuyDip Nov. 27 at 10:19 PM

0 · Reply

BubbaHoTep Nov. 27 at 7:17 PM

$SMMT $PLSE Happy Thanksgiving all!

1 · Reply

TruthBroker2 Nov. 26 at 4:02 PM

$SMMT $PLSE Lfggg

0 · Reply

TruthBroker2 Nov. 26 at 2:54 PM

$ISRG $PLSE

0 · Reply

TruthBroker2 Nov. 26 at 1:14 PM

$ISRG $PLSE #1

0 · Reply

Iightning Nov. 26 at 4:01 AM

1ightning® Options Trade Alert (Actionable) | Buy $PLSE Dec 19 $18 Call | Enter: $1.98 Exit: $3.78 | Profit: 91.35% ROI | https://1ightning.com

0 · Reply

TruthBroker2 Nov. 25 at 7:04 PM

$PLSE $ISRG

0 · Reply

Iightning Nov. 25 at 2:07 PM

1ightning® Options Trade Alert (Actionable) | Buy $PLSE Dec 19 $18 Call | Enter: $1.98 Exit: $3.78 | Profit: 91.35% ROI | https://1ightning.com

0 · Reply

TruthBroker2 Nov. 25 at 10:08 AM

$PLSE

0 · Reply

Iightning Nov. 25 at 3:00 AM

1ightning® Options Trade Alert (Actionable) | Buy $PLSE Dec 19 $18 Call | Enter: $1.98 Exit: $3.78 | Profit: 91.35% ROI | https://1ightning.com

0 · Reply

TruthBroker2 Nov. 24 at 3:51 PM

$PLSE 20.

0 · Reply

Iightning Nov. 22 at 12:15 AM

1ightning® Options Trade Alert (Actionable) | Buy $PLSE Dec 19 $18 Call | Enter: $1.98 Exit: $2.60 | Profit: 31.45% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 3:35 AM

1ightning® Options Trade Alert (Actionable) | Buy $PLSE Dec 19 $18 Call | Enter: $1.98 Exit: $2.60 | Profit: 31.45% ROI | https://1ightning.com

0 · Reply

Market Cap	927.74M
Revenue (ttm)	0.00
Net Income (ttm)	-53.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	88,300
Avg Vol	171,934
Day's Range	N/A - N/A
Shares Out	67.77M
Stochastic %K	61%
Beta	1.80
Analysts	Sell
Price Target	$22.00